Treatment
S-1 clinical trials
We’re tracking 801 recruiting studies that include S-1, each written for real people, not researchers, below.
Recruiting studies
- NCT07086300Recruiting
Acupuncture with immunotherapy for older lung cancer patients
This trial tests whether adding electroacupuncture (a gentle, needle-based therapy) to a standard immunotherapy drug (PD-1 inhibitor) can help older adults with advanced lung cancer. It may improve treatment response and quality of life.
Tianjin, Tianjin MunicipalityAges 65–100 - NCT07125547RecruitingPhase 2
Immunotherapy and chemo before surgery for ureteral cancer
This trial tests a combination of immunotherapy (tislelizumab) and chemotherapy (nab-paclitaxel) given before surgery for ureteral cancer. The goal is to see if the treatment shrinks the tumor and makes the surgery more effective.
Tianjin, Outside U.S.Ages 18 years+ - NCT07143318RecruitingPhase 1
First-in-Human study of KLA578-1 for injection in healthy volunteers
This trial tests a new investigational drug for the first time in people. It will study how the drug is processed by the body in healthy volunteers. If you are a generally healthy adult, you may be able to help with this important early research.
Changsha, HunanAges 18–45 - NCT07178223Recruiting
Thumb base replacement surgery for arthritis
This study tests a new type of thumb joint replacement surgery for people with arthritis at the base of the thumb. The goal is to see if it relieves pain and improves function better than current treatments.
StockholmAges Any age - NCT07198165RecruitingPhase 2
Short radiation followed by chemo plus bevacizumab with or without immunotherapy for rectal cancer
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemoradiation and targeted therapy improves outcomes for locally advanced rectal cancer. It is for patients who have not had prior treatment and do not have certain genetic markers (BRAF mutation or MSI-H).
ShanghaiAges 18–75 - NCT07207148Recruiting
Ocrelizumab and weight-loss drugs for MS
This study looks at combining ocrelizumab (an MS treatment) with GLP-1 agonists (like Ozempic, used for weight management) in people with MS. It aims to see if the combination is safe and beneficial.
Chicago, IllinoisAges 18–70 - NCT07236190RecruitingPhase 2
Using brain markers to test NPC-1 for Alzheimer's
This trial tests whether NPC-1, a new drug, can help people with early memory changes or Alzheimer's. Your blood or PET scan will show if you have Alzheimer's-related brain changes, which is required for this study.
Boston, MassachusettsAges 55 years+ - NCT07239661Recruiting
Acupuncture plus immunotherapy for advanced lung cancer
This trial tests whether adding electroacupuncture to a PD-1 inhibitor (a type of immunotherapy) can help people with advanced non-small cell lung cancer who have limited activity levels. It may improve treatment response and quality of life.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07279077RecruitingPhase 2
Low-dose radiation with chemo and immunotherapy for high-risk colon cancer
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of high-risk colon cancer that has not spread. The goal is to see if this approach can shrink the tumor before surgery and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07359040Recruiting
Testing a new drug before surgery for lung cancer
This trial studies whether a new drug called Ivonescimab can improve outcomes when given before surgery for non-small cell lung cancer. It may help shrink tumors and make them easier to remove.
Beijing, Beijing MunicipalityAges Any age - NCT02821013RecruitingPhase 3
Testing how long to take PD-1 therapy for melanoma
This trial studies whether people with metastatic melanoma should take PD-1 immunotherapy continuously or only for a limited time. It aims to find a schedule that keeps the cancer under control while possibly reducing treatment burden.
Victoria, MilduraAges 18 years+ - NCT06794086RecruitingPhase 3
SBRT and immunotherapy for colorectal cancer liver metastases
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
Guangzhou, GuangdongAges 18–75 - NCT02796937Enrolling by invitationPhase 3
Long-term safety study of a blood protein for Alpha-1
This study checks how safe a prescribed blood protein medicine (alpha-1 proteinase inhibitor) is over the long term in people with Alpha-1 antitrypsin deficiency. You may join if you already finished an earlier study or if your lung function has been declining.
Phoenix, ArizonaAges 20–72 - NCT07398300Recruiting
How GIP and GLP-1 affect insulin and blood flow in the body
This study uses a special full-body PET scan to see how two natural hormones, GIP and GLP-1, affect how your body uses sugar and moves blood. It includes healthy volunteers and people with type 2 diabetes who are on metformin only.
CopenhagenAges 23–64 - NCT07404332RecruitingPhase 1
Combination therapy for tumors resistant to immunotherapy
This trial tests a combination of two drugs (5-Azacitidine and a PD-1/PD-L1 inhibitor) for people whose solid tumors stopped responding to standard PD-1/PD-L1 immunotherapy alone. The goal is to see if this new combination can help shrink the tumor or slow its growth.
Iowa City, IowaAges 18–99 - NCT07407894Recruiting
Probiotic study for healthy aging in midlife adults
This trial tests a probiotic supplement called iVS-1 to see if it can slow biological aging in healthy adults aged 40-75. Researchers want to learn if this probiotic may help support health as you age.
New Port Richey, FloridaAges 40–75 - NCT07449572RecruitingPhase 1
Safety study of HT31-1 for healthy volunteers
This trial tests a new drug called HT31-1 to see if it's safe in healthy people. It looks at how the drug moves in your body and if it causes side effects. This is a first step before testing it in patients with ARDS (a serious lung condition).
Richmond, VirginiaAges 18–65 - NCT07458529RecruitingPhase 2
Chemoradiation plus immunotherapy with or without probiotics for rectal cancer
This trial tests adding an immunotherapy drug (tislelizumab) and a probiotic to standard chemoradiation for locally advanced rectal cancer that has not spread. The goal is to see if the probiotic helps the treatment work better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07489989RecruitingPhase 2
Combination therapy to boost CAR-T for B-cell lymphoma
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
Beijing, Beijing MunicipalityAges 18–85 - NCT07499440RecruitingPhase 2
Testing a new medicine, HB-1, for PTSD
This trial tests an experimental medicine, HB-1, as a potential treatment for PTSD. It is a 8-week study to see if the medicine is safe and if it reduces PTSD symptoms. You must have a stable medication routine and be willing to take the study pill daily.
Bruce, Australian Capital TerritoryAges 18–65 - NCT07504471RecruitingPhase 2
Bicarbonate plus chemo and immunotherapy for pancreatic cancer liver spread
This trial tests adding sodium bicarbonate to a chemotherapy plus immunotherapy regimen for pancreatic cancer that has spread to the liver. The goal is to see if this combination helps shrink tumors and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07572513Recruiting
How special carbohydrates affect hormone release in healthy adults
This study tests whether eating carbohydrates that digest slowly can naturally boost a hormone called GLP-1, which helps control blood sugar and appetite. Researchers want to understand if this might help people manage their weight and metabolism.
West Lafayette, IndianaAges 18–45 - NCT07605572Recruiting
GLP-1 drugs and dry eye disease in type 2 diabetes
This study tests whether a diabetes and weight-loss medication called GLP-1 receptor agonists affects dry eye disease. Researchers want to see if this medication helps or worsens dry eyes in people with type 2 diabetes and obesity.
AthensAges 18 years+ - NCT07616037RecruitingPhase 2
New hormone treatment for polycystic ovary syndrome
This study tests a new medication that combines two hormone-like drugs to treat polycystic ovary syndrome (PCOS), a condition affecting ovulation and hormone balance. The trial aims to see if this dual-action drug can improve irregular periods and other PCOS symptoms better than current treatments.
Shanghai, Shanghai MunicipalityAges 18–40
Common questions
- Are there clinical trials studying S-1?
- Yes. Clin2 currently lists 801 recruiting studies that include S-1, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a S-1 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is S-1 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether S-1 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.